在非小细胞肺癌中KRAS的现有前景
1Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637. USA.
Current problems in cancer
|June 16, 2024
概括
在非小细胞肺癌 (NSCLC) 中准基尔斯鼠肉瘤 (KRAS) 突变显示出有前途. 已批准的KRAS G12C抑制剂和新兴疗法为NSCLC患者提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 呈现出复杂的基因组格局,经常涉及基因突变的原型瘤基因,如基尔斯大鼠肉瘤 (KRAS) 和表皮生长因子受体 (EGFR).
- 大约40%的肺腺癌病例携带激活KRAS突变,主要位于G12位置 (G12C,G12V,G12D),无论吸烟状态如何.
- KRAS-突变的NSCLC通常呈现出更高的瘤突变负担和增加的PD-1表达,与与其他瘤驱动因素相比,与免疫治疗的增强反应相关.
研究的目的:
- 审查目前针对NSCLC中KRAS突变的治疗策略.
- 要总结对KRAS G12C突变NSCLC有效的药物组合.
- 讨论KRAS G12D的新兴抑制剂和针对KRAS的新疗法.
主要方法:
- 在NSCLC中针对KRAS向治疗的临床前和临床研究的文献综述.
- 对已批准的KRAS G12C抑制剂 (索托拉西布,阿达格拉西布) 和它们的组合疗法进行分析.
- 探索正在进行的对新型KRAS抑制剂的研究,包括那些针对G12D突变的抑制剂.
主要成果:
- 直接准KRAS突变已在转移性NSCLC中显示出有效性.
- 两种KRAS G12C抑制剂,索托拉西布和阿达格拉西布,已获得FDA批准,目前正在对各种药物组合进行调查.
- 开发新型疗法,包括即将推出的G12D抑制剂,正在扩大KRAS突变NSCLC的治疗选择.
结论:
- 向KRAS突变代表了NSCLC治疗的重大进步.
- 组合疗法和新药对于克服耐药性和改善KRAS突变NSCLC的结果至关重要.
- 对KRAS G12D抑制剂和其他新型治疗方法的持续研究对更广泛的患者群体具有前景.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:38The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K